Nuno Arantes‐Oliveira is an entrepreneur and professional advisor with a scientific background and an interest in technological innovation, particularly in the Life Sciences and in Healthcare. As a graduate student, Nuno worked on the genetics of aging at the University of California San Francisco (UCSF) under Prof. Cynthia Kenyon, and led the efforts to achieve the largest lifespan extension ever observed in any living being (more than 6‐fold), which in turn originated a string of papers, including three in the journal Science. After obtaining his PhD Nuno worked as a post-doc on Innovation and Entrepreneurship in Biotechnology, and at the same time became the first Managing Director of a pioneer technology-transfer company focused on commercializing scientific breakthroughs stemming from Portuguese R&D organizations. Later Nuno launched Alfama, one of the first drug development companies to originate from Portugal, which was then voted the Best Start-up in Europe. Alfama, Inc. was incorporated in the United States (Cambridge, MA) and through growth and acquisitions became the dominant player in the field of carbon monoxide (CO)-based therapies, before being itself acquired by Proterris, Inc., of Boston. Nuno also founded Coimbra Genomics S.A. (voted a top‐3 promise in European e-Health, 2015) and helped launch the Innovation and Translational Research Units of IPATIMUP, a leading cancer research institute (now part of I3S). In the meantime, Nuno served as President of P‐BIO – Portugal’s Biotechnology Industry Organization from 2011 to 2015 and sat on the board of Health Cluster Portugal from 2008 to 2013. Nuno has had multiple other board, advisory and expert roles internationally, including with Government authorities and top‐tier research organizations, and has negotiated and implemented business and scientific collaborations in Europe, the U.S., China, Africa and Latin America. Through his personal company Nuno owns a pediatric specialties clinic in Lisbon and advises technology-based ventures in five countries, in fields ranging from new oncology drugs (Revere Pharmaceuticals, Boston, MA) to microbiome-based therapies (PharmaBiome, Zurich). Presently Nuno is also an advisor to the Rectory of NOVA University in Lisbon, serves as the Chairman of the Board of pioneer shellfish aquaculture startup Oceano Fresco S.A., and is the Chairman of the Investment Committee of 200M, a venture capital co-investment fund. Up until December 2018 Nuno was invited assistant professor of the MIT‐Portugal Program, and in January 2019 he became invited associate professor of NOVA University School of Business and Economics (NOVA-SBE), where he teaches Science-based entrepreneurship.